CD33 and lymphoma: The NK-92 cell line engineered to express anti-CD33 or anti-CD7 linked to TCR zeta, CD28 and 4-1BB signaling domains are undergoing clinical trials for CD33+ AML (NCT02944162) or CD7+ relapsed or refractory leukemia and lymphoma (NCT02742727), respectively.